(Q45351775)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

title

Translational PK/PD modeling for cardiovascular safety assessment of drug candidates: Methods and examples in drug development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

author name string

Nicolas Frances

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Christophe Meille

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Andrea Greiter-Wilke

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Alexander Hillebrecht

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

Thierry Lavé

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

language of work or name

1 reference

28 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

Journal of Pharmacological and Toxicological Methods

19 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

volume

70

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

19 March 2020

page(s)

73-85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24879942%20AND%20SRC:MED&resulttype=core&format=json

Arrhythmogenic liability screening in cardiovascular safety pharmacology: commonality between non-clinical safety pharmacology and clinical thorough QT (TQT) studies.

19 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Effects of torcetrapib in patients at high risk for coronary events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Drugs, hERG and sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Calculation of QT shift in non clinical safety pharmacology studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Cardiovascular monkey telemetry: sensitivity to detect QT interval prolongation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

A translational assessment of preclinical versus clinical tools for the measurement of cardiac contractility: comparison of LV dP/dt(max) with echocardiography in telemetry implanted beagle dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

A new method for determining allowable daily intakes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Comparison of four basic models of indirect pharmacodynamic responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Organising evidence on QT prolongation and occurrence of Torsades de Pointes with non-antiarrhythmic drugs: a call for consensus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Prognostic Significance of Quantitative QRS Duration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

The no-observed-adverse-effect-level in drug safety evaluations: use, issues, and definition(s)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Is it possible to estimate the parameters of the sigmoid Emax model with truncated data typical of clinical studies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Cardiac Safety Implications of hNav1.5 Blockade and a Framework for Pre-Clinical Evaluation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

The impact of drug-induced QT interval prolongation on drug discovery and development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

A pharmacokinetic-pharmacodynamic model for cardiovascular safety assessment of R1551

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

The 'overly-sensitive' heart: sodium channel block and QRS interval prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Comparison of electrocardiographic analysis for risk of QT interval prolongation using safety pharmacology and toxicological studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Pharmacokinetic-pharmacodynamic modeling of telmisartan using an indirect response model in spontaneously hypertensive rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Novel probabilistic method for precisely correcting the QT interval for heart rate in telemetered dogs and cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Preclinical QT safety assessment: cross-species comparisons and human translation from an industry consortium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

A novel strategy for physiologically based predictions of human pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

A pharmacokinetic-pharmacodynamic model for the quantitative prediction of dofetilide clinical QT prolongation from human ether-a-go-go-related gene current inhibition data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Drug-induced q-T prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Significance of QRS complex duration in patients with heart failure

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Reuptake inhibitors of dopamine, noradrenaline, and serotonin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Can the pharmaceutical industry reduce attrition rates?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Statistical properties of the NOAEL.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Dose-response and threshold-mediated mechanisms in mutagenesis: statistical models and study design

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Statistical model to estimate a threshold dose and its confidence limits for the analysis of sublinear dose-response relationships, exemplified for mutagenicity data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Development of translational pharmacokinetic-pharmacodynamic models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Diversity of mechanism-based pharmacodynamic models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

The value added by measuring myocardial contractility 'in vivo' in safety pharmacological profiling of drug candidates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Lessons from 60 years of pharmaceutical innovation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

A novel predictive pharmacokinetic/pharmacodynamic model of repolarization prolongation derived from the effects of terfenadine, cisapride and E-4031 in the conscious chronic av node--ablated, His bundle-paced dog.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Comparison of the QT interval response during sinus and paced rhythm in conscious and anesthetized beagle dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Pharmacokinetic-pharmacodynamic modeling of drug-induced effect on the QT interval in conscious telemetered dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Translational pharmacokinetic-pharmacodynamic modeling of QTc effects in dog and human

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Resting heart rate pattern during follow-up and mortality in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Modelling the cardiovascular effects of ephedrine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Prognostic value of prolonged ventricular repolarization following myocardial infarction: the BHAT experience. The BHAT Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Principles of safety pharmacology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Thresholds in chemical carcinogenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Drug-induced prolongation of the QT interval

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

An improved method for adjusting the QT interval for heart rate (the Framingham Heart Study)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Modelling of individual pharmacokinetics for computer-aided drug dosage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Pharmacokinetic-pharmacodynamic modelling of the effect of Moxifloxacin on QTc prolongation in telemetered cynomolgus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004

Estimation of safe doses: critical review of the hockey stick regression method

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2014.05.004